Actively Recruiting
Phase 1 Study to Test Safety and Tolerability of E coli Vaccines Given by Injection to Healthy Adults Aged 18 to 64
Led by Pfizer · Updated on 2026-04-30
310
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying an investigational vaccine designed to protect healthy adults against Escherichia coli E coli. This Phase 1 clinical trial aims primarily to assess the safety and tolerability of several candidate E coli vaccines administered intramuscularly. The study involves healthy adults aged 18 to 64 years without serious medical conditions. Participants will be randomly assigned to receive one of several experimental E coli vaccine doses or a placebo. Each participant receives injections on day 1 and day 180, following a 0 and 6-month schedule. The study is double-blinded, meaning neither the participants nor the investigators know who receives the vaccine or placebo during the trial. During the study, participants will be monitored closely for local and systemic reactions within 7 days after each vaccination. Researchers will also track adverse events from the first vaccination through 12 months after the last dose. Safety assessments include medical exams and recording any serious or medically attended health issues. The total participation lasts up to 18 months with regular visits and safety follow-up.
CONDITIONS
Brief Title
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
